Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02856646 · ClinicalTrials.gov registry record
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 290
- Enrollment target
NCT02856646 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 290 participants.
The verdict
NCT02856646 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 290 participants
- Enrollment target
Study Summary
The purpose of this study is to gather data on patients diagnosed with and treated for classical Hodgkin Lymphoma (cHL). It aims to closely observe how treatment for cHL is rendered, as well as assess the outcome of those treatment options and their impact on quality of life. Additional analyses will also attempt to identify prognostic or predictive biomarkers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2016-10-07 |
| Est. Completion | 2020-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02856646
The ClinicalTrials.gov registry entry for NCT02856646 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02856646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02856646 about?
NCT02856646 is a clinical study titled "Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices". The purpose of this study is to gather data on patients diagnosed with and treated for classical Hodgkin Lymphoma (cHL). It aims to closely observe how treatment for cHL is rendered, as well as assess the outcome of those treatment options and their impact on quality of life. Additional analyses wil...
What is the current status of trial NCT02856646?
This trial is currently completed. The enrollment target is 290 participants. The study started on 2016-10-07. Estimated completion is 2020-09-30.
Who is sponsoring clinical trial NCT02856646?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.